logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences 'very excited' about potential for nasal delivery of Foralumab for coronavirus

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) Dr Howard Weiner speaks to Proactive's Polly Middlehurst following the news it's submitted a patent application covering the potential use of nasally-administered and orally taken Foralumab for the treatment of COVID-19. Dr Weiner is chairman of Tiziana’s scientific advisory board. The methods of delivering the fully human anti-CD3 monoclonal antibody (mAb) could potentially modulate or stimulate the immune system to suppress cytokine storms and therefore reduce respiratory failure in coronavirus patients.

Quick facts: Tiziana Life Sciences PLC

Price: 219.8 GBX

AIM:TILS
Market: AIM
Market Cap: £370.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences has potential to 'revolutionise treatment in...

Proactive Research analyst Emma Ulker discusses what she describes as the ground-breaking approach Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) is taking in the field of monoclonal antibodies. She says their lead programme Foralumab is notable in that not only is it the only fully human...

2 weeks, 2 days ago

2 min read